Medpage Today on MSN6mon
Cytokine Release Syndrome and Neurotoxicity After CAR T-Cell TherapyThe incidence of CRS has been reported to range from 57% to 93% and ICANS from 20% to 70%. The frequency and severity of ...
Zacks Investment Research on MSN3d
OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by ParatekShares of OptiNose OPTN soared 52.5% on Thursday after the company announced that it is set to be acquired by Paratek ...
In myeloma treatment, acute CRS is a common but treatable AE associated with CAR T-cell therapy and bispecific antibodies, ...
Siltuximab effectively treated patients who experienced common adverse events after chimeric antigen receptor T-cell therapy, ...
Dr. Deepa Jagadeesh discusses Ordspono's potential FDA approval for relapsed/refractory follicular lymphoma, highlighting its manageable toxicity and low CRS rate.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback